Mesoblast Stock Analysis

Mesoblast Stock Analysis Notes

The book value of the company was now reported as 0.42. The company recorded a loss per share of 1.05. Mesoblast had not issued any dividends in recent years. The entity had 1:2 split on the 10th of January 2024. Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Mesoblast operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. To find out more about Mesoblast contact FACP FACRA at 61 3 9639 6036 or learn more at https://www.mesoblast.com.

Mesoblast Investment Alerts

Mesoblast Upcoming and Recent Events

Mesoblast Largest EPS Surprises

View All Earnings Estimates

Mesoblast Environmental, Social, and Governance (ESG) Scores

Mesoblast Thematic Classifications

Mesoblast Stock Institutional Investors

Note, although Mesoblast's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Mesoblast Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.14 B.

Mesoblast Profitablity

Management Efficiency

Mesoblast has return on total asset (ROA) of (0.0541) % which means that it has lost $0.0541 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1791) %, meaning that it created substantial loss on money invested by shareholders. Mesoblast's management efficiency ratios could be used to measure how well Mesoblast manages its routine affairs as well as how well it operates its assets and liabilities. As of the 20th of March 2025, Return On Tangible Assets is likely to drop to -1.14. In addition to that, Return On Capital Employed is likely to grow to -0.13. At this time, Mesoblast's Other Current Assets are very stable compared to the past year. As of the 20th of March 2025, Total Current Assets is likely to grow to about 116.5 M, while Total Assets are likely to drop about 583.1 M.

Technical Drivers

As of the 20th of March, Mesoblast secures the Risk Adjusted Performance of 0.0686, downside deviation of 4.34, and Mean Deviation of 4.41. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mesoblast, as well as the relationship between them.

Mesoblast Price Movement Analysis

Mesoblast Outstanding Bonds

Mesoblast Predictive Daily Indicators

Mesoblast Corporate Filings

Mesoblast Forecast Models

Mesoblast's time-series forecasting models are one of many Mesoblast's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Mesoblast's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Mesoblast prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Mesoblast shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Mesoblast. By using and applying Mesoblast Stock analysis, traders can create a robust methodology for identifying Mesoblast entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Mesoblast analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Mesoblast analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Mesoblast stock analysis indicators help investors evaluate how Mesoblast stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Mesoblast shares will generate the highest return on investment. By understating and applying Mesoblast stock analysis, traders can identify Mesoblast position entry and exit signals to maximize returns.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.